cmc4 Antibody

What is CMC4 protein and where is it localized in cells?

CMC4 (also known as MTCP1, MTCP1NB, p8, or p8MTCP1) is a protein that primarily localizes to the mitochondrion, specifically in the mitochondrial intermembrane space. This protein was initially identified through its involvement in t(X;14) translocations associated with mature T-cell proliferations. The gene has a complex structure with a common promoter and 5' exon spliced to different sets of 3' exons, encoding different proteins. CMC4 represents the downstream 8 kDa protein that localizes to mitochondria . Understanding this localization is crucial for designing experiments to study its function in cellular processes.

What types of CMC4 antibodies are currently available for research applications?

Current research indicates availability of multiple CMC4 antibodies with varied characteristics:

According to comprehensive antibody databases, there are at least 71 different CMC4 antibodies available from 18 different providers, offering researchers multiple options depending on their specific experimental needs .

What are the validated applications for CMC4 antibodies in research protocols?

CMC4 antibodies have been validated primarily for the following applications:

• Immunohistochemistry (IHC): Successfully used on human thyroid cancer and human brain samples

• Western Blotting (WB): For detecting CMC4 protein expression levels in cell and tissue lysates

• ELISA: For quantitative detection of CMC4 in various samples

• Immunocytochemistry (ICC): For cellular localization studies

When selecting an antibody for your research, prioritize those with validation data specific to your application and experimental model. The strongest validation appears to be for IHC applications, with specific dilution recommendations available (1:100-1:300) .

How should researchers optimize antibody dilution for CMC4 detection in IHC applications?

For optimal CMC4 detection in IHC applications, multiple sources recommend a dilution range of 1:100-1:300 . The optimization process should include:

• Begin with a titration experiment using the recommended dilution range (1:100, 1:200, 1:300)

• Use positive control tissues (verified samples include human thyroid cancer and human brain tissue)

• Evaluate staining intensity, background levels, and specificity at each dilution

• Consider tissue-specific factors that might influence optimal antibody concentration

• Document optimal dilution for reproducibility in future experiments

The phosphate-buffered solution (pH 7.4) containing 0.05% stabilizer and 50% glycerol used in commercially available CMC4 antibodies should be considered when calculating final working dilutions .

What controls should be implemented when validating CMC4 antibody specificity?

Rigorous validation of CMC4 antibody specificity requires multiple control strategies:

• Positive Controls: Use tissues with known CMC4 expression (human thyroid cancer and brain tissue have been verified)

• Negative Controls:

  • Primary antibody omission

  • Use tissues known to lack CMC4 expression

  • Isotype controls (IgG from the same species)

• Competitive Inhibition: Pre-incubate antibody with immunizing peptide (recombinant protein of human CMC4)

• Knockout/Knockdown Validation: Test antibody in CMC4 knockout or knockdown samples

• Multiple Antibody Validation: Compare staining patterns from different CMC4 antibodies targeting distinct epitopes

This comprehensive approach ensures that observed signals truly represent CMC4 protein rather than non-specific binding or background.

How can researchers investigate the potential role of CMC4 in cancer development?

Given that CMC4 (also known as chromosome transmission fidelity protein 4) plays a role in maintaining genomic stability and ensuring accurate chromosome segregation during cell division, and its dysregulation has been linked to various cancers , researchers should consider:

• Expression Analysis: Compare CMC4 expression levels between normal and cancerous tissues using validated antibodies in IHC and Western blot

• Subcellular Localization Studies: Investigate whether CMC4 localization changes in cancer cells (particularly important given its mitochondrial localization)

• Co-localization Studies: Examine association with other mitochondrial proteins and markers of genomic instability

• Functional Studies: Knockdown or overexpression of CMC4 followed by assessment of:

  • Chromosome segregation fidelity

  • Mitochondrial function

  • DNA damage response

  • Cell cycle progression

• Clinical Correlation: Analyze CMC4 expression in patient samples in relation to clinical outcomes and therapeutic responses

These approaches can help elucidate the functional significance of CMC4 in cancer biology and potential therapeutic implications.

What strategies can address weak or inconsistent CMC4 staining in immunohistochemistry?

When encountering weak or inconsistent CMC4 staining in IHC applications, consider the following troubleshooting strategies:

• Antibody Concentration: Increase antibody concentration within the recommended range (1:100-1:300)

• Antigen Retrieval Optimization:

  • Test different antigen retrieval methods (heat-induced vs. enzymatic)

  • Optimize buffer pH and heating time

• Fixation Assessment: Different fixatives can affect CMC4 epitope accessibility

• Incubation Parameters:

  • Extend primary antibody incubation time (overnight at 4°C)

  • Optimize temperature (4°C vs. room temperature)

• Detection System Enhancement:

  • Use amplification systems (e.g., tyramide signal amplification)

  • Consider biotin-conjugated secondary antibodies

• Antibody Storage Evaluation: Check for potential degradation due to improper storage or multiple freeze-thaw cycles

Document all optimization steps to ensure reproducibility in future experiments.

How should researchers design experiments to investigate CMC4 function in mitochondrial processes?

Given CMC4's localization to the mitochondrial intermembrane space , experimental design should include:

• Subcellular Fractionation:

  • Isolate mitochondria using differential centrifugation

  • Further separate mitochondrial subcompartments to confirm intermembrane space localization

  • Validate fractionation purity using compartment-specific markers

• Co-localization Studies:

  • Use confocal microscopy with CMC4 antibodies alongside established mitochondrial markers

  • Include markers for different mitochondrial subcompartments (outer membrane, inner membrane, matrix)

• Interaction Partners:

  • Perform co-immunoprecipitation using CMC4 antibodies

  • Identify binding partners through mass spectrometry

  • Validate interactions through reciprocal co-IP or proximity ligation assays

• Functional Assessments:

  • Measure mitochondrial functions (respiration, membrane potential, ROS production) after CMC4 manipulation

  • Assess impact on mitochondrial morphology and dynamics

• Disease Relevance:

  • Examine CMC4 expression and localization in models of mitochondrial disease

  • Investigate potential alterations in CMC4 function in cancer cells with mitochondrial abnormalities

What are the optimal storage conditions for maintaining CMC4 antibody activity?

For optimal preservation of CMC4 antibody activity:

• Storage Temperature: Store at -20°C for long-term stability

• Aliquoting Strategy: Divide into small aliquots upon receipt to minimize freeze-thaw cycles

• Freeze-Thaw Cycles: Strictly avoid repeated freeze-thaw cycles as they can significantly reduce antibody activity

• Working Solution Storage: Keep working dilutions at 4°C for short-term use (typically 1-2 weeks)

• Shipping Conditions: Upon receipt after shipping with ice packs, immediately store at the recommended temperature

• Buffer Consideration: The standard formulation in phosphate buffered solution (pH 7.4) with 0.05% stabilizer and 50% glycerol helps maintain stability

Proper storage is crucial for maintaining antibody performance throughout the product's 12-month validity period .